GlassScriptPhysician profile
Jade Clinton
NPI 1760065767
$2,839.19
in general payments reported to CMS, 2019-2025
25 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $450 · 2023: $545 · 2024: $318 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.03 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $607.38 | 2022-2025 | |
| Axsome Therapeutics, INC. | $334.05 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $317.21 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $315.60 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $201.44 | 2022-2023 | Rexulti |
| Lundbeck LLC | $150.31 | 2022-2025 | Rexulti, Brintellix |
| Teva Pharmaceuticals USA, INC. | $126.21 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $125.64 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $100.36 | 2022-2024 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $92.39 | 2023-2024 | Lumryz |
| Sunovion Pharmaceuticals INC. | $72.37 | 2022 | |
| Tris Pharma INC | $67.16 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $53.87 | 2024-2025 | Spravato |
| Corium, LLC | $45.35 | 2023 | Azstarys |
| Inspire Medical Systems, INC. | $29.20 | 2024 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.87 | 2022-2024 | Trintellix |
| Alkermes, INC. | $27.98 | 2025 | Vivitrol |
| Philips North America LLC | $27.84 | 2025 | Home Pi Undivided |
| Merck Sharp & Dohme LLC | $21.84 | 2023 | Belsomra |
| Validus Pharmaceuticals LLC | $21.11 | 2023 | Equetro |
| Bausch Health US, LLC | $18.14 | 2024 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $14.68 | 2023 | Secuado |
| Collegium Pharmaceutical, INC. | $14.01 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $13.91 | 2025 | Cobenfy |
| Alfasigma USA, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Clinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.